Pfizer (NYSE:PFE) Hits New 12-Month High – What’s Next?

Pfizer Inc. (NYSE:PFE)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $29.27 and last traded at $29.1190, with a volume of 7,820,373 shares. The stock had previously closed at $28.37.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Sec61 drug-discovery partnership expands Pfizer’s pipeline: Pfizer agreed to collaborate with Enodia Therapeutics in a deal valued at up to $500 million to identify and advance small-molecule candidates targeting Sec61. Enodia will provide its proprietary discovery platform, while Pfizer will oversee clinical, regulatory and commercial development. The agreement gives Pfizer another potential source of medicines across multiple disease areas, although financial returns remain dependent on successful development. Pfizer partners with Enodia Therapeutics in $500m drug deal
• Positive Sentiment: Upcoming IDWeek presentations highlight infectious-disease research: Pfizer plans to present more than 50 abstracts, including 12 oral presentations, at the October 21–24 IDWeek 2026 conference. The data will cover prevention and treatment programs and could provide investors with updates on future growth products beyond declining COVID-related revenue. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: Technical and earnings-estimate support: Pfizer recently moved above its 50-day moving average, while Erste Group Bank raised its 2026 EPS forecast slightly to $2.97 from $2.96. Pfizer also previously reported quarterly revenue and adjusted earnings above analyst expectations.
• Neutral Sentiment: Analyst stance remains cautious: J.P. Morgan maintained a Hold rating, suggesting that pipeline opportunities and valuation support are balanced by execution risks. J.P. Morgan Keeps Their Hold Rating on Pfizer
• Negative Sentiment: Dividend sustainability and patent risks remain overhangs: Commentary continues to flag Pfizer’s roughly 6% dividend yield, high payout ratio and upcoming patent expirations. Declining COVID-product sales also leave the company dependent on new launches and pipeline execution to sustain earnings growth.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Scotiabank raised their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Finally, BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Stock Performance

The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a 50-day simple moving average of $27.81 and a 200 day simple moving average of $26.52. The company has a market cap of $166.75 billion, a price-to-earnings ratio of 38.48, a price-to-earnings-growth ratio of 1.92 and a beta of 0.32.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently bought and sold shares of the company. Perpetual Ltd lifted its holdings in shares of Pfizer by 11.8% in the 3rd quarter. Perpetual Ltd now owns 150,513 shares of the biopharmaceutical company’s stock valued at $4,293,000 after buying an additional 15,937 shares during the period. Scott Capital Advisors LLC acquired a new position in Pfizer during the third quarter worth $405,000. HF Advisory Group LLC raised its position in Pfizer by 7.8% in the third quarter. HF Advisory Group LLC now owns 110,318 shares of the biopharmaceutical company’s stock worth $3,146,000 after acquiring an additional 7,940 shares in the last quarter. Gallagher Capital Advisors LLC raised its position in Pfizer by 1.5% in the third quarter. Gallagher Capital Advisors LLC now owns 143,311 shares of the biopharmaceutical company’s stock worth $4,087,000 after acquiring an additional 2,069 shares in the last quarter. Finally, Friday Financial acquired a new stake in Pfizer in the third quarter valued at $222,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.